In a retrospective analysis, patients with colon cancer taking GLP-1 agonists had a 62% lower risk of 5-year mortality ...

The study found that the five-year mortality rate was significantly lower among patients who were using GLP-1 receptor ...

Patients with colon cancer using GLP-1 receptor agonists (the class of drugs behind treatments like Ozempic, Wegovy, and ...

GLP-1 receptor agonists like Ozempic and Wegovy may increase survival among patients with colon cancer. | Drug Discovery And ...

While drugs like Wegovy, Ozempic and Mounjaro are hailed for regulating blood sugar and helping people lose weight, new ...

Survival rates also varied significantly by stage. In the combined analysis for men and women without metastasis, the ...

People with colon cancer who took GLP-1 drugs were less likely to die within 5 years than people not on GLP-1s, a new study ...

A UC San Diego study reveals GLP-1 receptor agonists, like Ozempic, may significantly reduce colon cancer death rates.

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...

GLP-1 receptors - the drugs behind Ozempic and Mounjaro - could have great benefits for colon cancer patients, the study ...

Don’t wait for the first symptom. Start regular colorectal cancer screening at 45 years old to stay proactive about your ...

The five-year survival rate for male and female patients in Japan who were diagnosed with pancreatic cancer between 2012 and 2015 came to 10.7 pct and 10.2 pct, respectively, the lowest among all ...